The lOR Institute of Oncology Research is part of the Research Division of the Oncology Institute of Southern Switzerland (IOSI), the comprehensive cancer center of the Ente Ospedaliero Cantonale (EOC), and is the main facility for basic and translational research at the IOSI.
The Institute is directed by Carlo Catapano MD, PhD and comprises different groups working in the areas of tumor biology, cancer genomics, molecular oncology and experimental therapeutics. The expertise available in the Institute spans from cell and molecular biology to molecular pharmacology, genomics and bioinformatics.
The Institute was established in 2003 formerly as the IOSI Laboratory of Experimental Oncology and is located within the Institute for Research in Biomedicine (IRB) in Bellinzona, Canton Ticino. The Institute currently employs about 60 researchers.
The Institute is also an integral component of the clinical research activities of the IOSI participating in translational studies and multi-center clinical trials and providing expertise, facilities and technical support for pharmacodynamics, pharmacogenomics and molecular follow-up studies.
As of 2017, the canton Ticino approved the integration of IOR into the new Faculty of Biomedical Sciences of the University of Lugano. The new Faculty will offer a Masters degree in Medicine (3 years) starting in 2020, in close collaboration with, on the academic side, ETH Zurich, the University of Basel and the University of Zurich, and with the Ente Ospedaliero Cantonale and the private clinics in Ticino for the bedside teaching.